北京招聘

职位描述：
BeiGene (Beijing) is searching for investigators in the field of in vivo pharmacology to provide expertise in developing our immuno-oncology pipelines. This individual will design and execute in vivo and translational studies in animal models to develop antibody drug and small molecular drugs, and assist in cross-functional development of our research strategy.

Responsibilities:
The primary responsibilities are to lead a group of scientists to discover and validate novel drug targets. The successful candidate will advance several aspects of BeiGene’s pre-clinical programs, using their skill set to accomplish the following responsibilities.
-Design and execute in vivo experiments to evaluate drug leads (biologics and small molecules).
-Collaborate with the broader scientific teams to design and execute experiments aimed at defining the mechanism(s) of action.
-Work with in vitro team (chemistry, biologics and cell biology) to develop in vivo models to test the activity of therapeutic leads in combination with established therapeutic agents and perform in-depth characterization of mechanism in these models.
-Engage colleagues in cross-disciplinary scientific discussion, present scientific data to internal and external audiences and keep abreast of relevant scientific literature.
-Present and communicate internally and to collaborators.

Qualifications:
-Expertise in cell biology, molecular biology, genetics, epigenetics and immunology.
-Broad knowledge of cancer biology
-Demonstrated ability to work collaboratively with peers across multiple areas
-Demonstrated scientific insight and problem solving, as evident in original research, contribution to drug discovery, or first authorship in publication or invention.
-Experience in managing scientists in a research organization
-Excellent analytical and organizational skills
-Excellent communications skills – bilingual in English and Chinese
-PhD degree required 举报 分享

百济神州是一家立足于科学的全球性生物科技公司，专注于开发创新、可负担的药物，旨在为全球患者改善治疗效果，提高药物可及性。目前公司广泛的药物组合包括40多款临床候选药物。公司通过加强自主研发能力和合作，加速推进多元、创新的药物管线开发。我们致力于在2030年前为全球20多亿人全面改善药物可及性。百济神州在全球五大洲打造了一支超过8,000人的团队。